ALNY position history
The shares of Alnylam Pharmaceuticals (ALNY) that DODGE & COX reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 5,372,100 shares, $1M, 0.66% of portfolio
- 2021 Q4: 5,431,068 shares, $921K, 0.57% of portfolio, Add +1.1%
- 2022 Q1: 5,475,668 shares, $894K, 0.54% of portfolio, Add +0.8%
- 2022 Q2: 5,258,956 shares, $767K, 0.53% of portfolio, Reduce −4.0%
- 2022 Q3: 4,889,297 shares, $979K, 0.74% of portfolio, Reduce −7.0%
- 2022 Q4: 4,590,782 shares, $1.1B, 0.75% of portfolio, Reduce −6.1%
- 2023 Q1: 3,894,535 shares, $780M, 0.53% of portfolio, Reduce −15.2%
- 2023 Q2: 3,789,525 shares, $720M, 0.48% of portfolio, Reduce −2.7%
- 2023 Q3: 3,747,155 shares, $664M, 0.45% of portfolio, Reduce −1.1%
- 2023 Q4: 7,348,620 shares, $1.4B, 0.89% of portfolio, Add +96.1%
- 2024 Q1: 3,811,480 shares, $570M, 0.33% of portfolio, Reduce −48.1%
- 2024 Q2: 3,780,185 shares, $919M, 0.55% of portfolio, Reduce −0.8%
- 2024 Q3: 3,622,535 shares, $996M, 0.56% of portfolio, Reduce −4.2%
- 2024 Q4: 3,540,262 shares, $833M, 0.48% of portfolio, Reduce −2.3%
- 2025 Q1: 3,351,762 shares, $905M, 0.52% of portfolio, Reduce −5.3%
- 2025 Q2: 3,197,096 shares, $1B, 0.59% of portfolio, Reduce −4.6%
- 2025 Q3: 2,321,230 shares, $1.1B, 0.57% of portfolio, Reduce −27.4%
- 2025 Q4: 1,964,415 shares, $781M, 0.42% of portfolio, Reduce −15.4%
- 2026 Q1: 1,929,253 shares, $638M, 0.35% of portfolio, Reduce −1.8%
- 2026 Q2: 1,955,393 shares, $589M, 0.31% of portfolio, Add +1.4%
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|